Reason for Recall: There is the potential for Hemostatic Bone Putty to ignite if contacted with electrosurgical cautery systems under certain conditions during surgery.
Since 2001, the University of New England has grown from less than $1 million in research funding to $22 million in 2012, thanks largely to a $10 million grant from the National Institutes of Health.
Less than two weeks after receiving U.S. Food and Drug Administration approval for its inhaled nitric oxide (NO) delivery system, Waltham-based GeNO LLC has received four patents for the product, bringing the company’s total to 16.
Ocular Therapeutix in Bedford will conduct a Phase 2 trial of a so-called punctum plug, which can be inserted near the eye, to deliver a sustained release dose of an existing drug, travoprost, to treat ocular hypertension (abnormal pressure in the eye) and glaucoma.
QuantiaMD, an online physician learning community, has hired former Verisk Health CEO Mike Coyne as its president. In his new role, Coyne will oversee the day-to-day operations of the Waltham-based health IT company and will report to QuantiaMD Chairman and CEO Eric Schultz.
Two North Carolina-based life science company service providers are opening a joint office in the Boston area as a way to extend their reach into New England.
CHELMSFORD, Mass.--(BUSINESS WIRE)--Aug 20, 2012--ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today it has entered into an agreement to license Inovise Medical, Inc.’s ambulatory AUDICOR ® technology as part of the advanced patient...
Ocular Therapeutix, spurred by positive results from a Phase I trial, launches a Phase II clinical study of a drug-releasing tear duct plug for treatment of ocular hypertension and glaucoma. Ocular Therapeutix launched a Phase II trial of its punctum plugs, a possible eye-drop killer for patients with glaucoma or ocular hypertension. The company's travoprost-releasing punctum plug, designed to fit into the entry of the tear duct, releases drug therapy to the surface of the eye over several months. News Well, Clinical Trials, Optical / Ophthalmicread more
Medtronic lands CE Mark approval in the European Union for its Viva/Brava line of defibrillators that adapt to patients' cardiac rhythms. Medtronic (NYSE:MDT) said it won CE Mark approval from the European Union for its Viva/Brava line of cardiac rhythm management devices. The medical device company said the Viva and Brava products, which are cardiac resynchronization therapy with defibrillation devices, feature a new algorithm it calls AdaptivCRT designed to optimize their CRT-D treatment. News Well, Cardiac Rhythm Management, CE Mark, Regulatory/Complianceread more
HAYWARD, Calif., Aug. 20, 2012 /- Ultra Clean Holdings, Inc. (Nasdaq: UCTT), a developer and supplier of critical subsystems, for the semiconductor capital equipment, medical device, energy, research, and flat panel industries, announced that Clarence Granger, Chairman and Chief Executive Officer, and Casey Eichler, Chief Financial Officer, will address the ThinkEqui...
Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of GlaucomaAugust 20, 2012 3:40 pm | by Bio-Medicine.Org | News | Comments
BEDFORD, Mass., Aug. 20, 2012 /- Following encouraging results from Ocular Therapeutix 's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma. Ocular Therapeutix's travoprost punctum plugs are inserted into the proxima...
W.L. Gore & Associates wins CE Mark approval in the European Union for its vascular prosthesis. W.L. Gore & Associates touted CE Mark approval in the European Union for its Gore Hybrid Vascular Graft. The device, which won FDA clearance in 2010, is indicated for use as replacement or bypass of diseased blood vessels while addressing common causes of graft failure. The graft is a vascular prosthesis designed to expand treatment options for blood outflow by working in the maximum number of sites available. News Well, CE Mark, Regulatory/Compliance, Stent Graftsread more
Covidien announces the 2nd recall in as many months after at least 4 patients were burned by grounding pads contained in some tumor ablation kits. Covidien (NYSE:COV) announced a new recall, its 2nd in as many months, after receiving reports of serious burn injuries associated with certain grounding pads contained in ablation device kits. News Well, Ablation, Recallsread more
CHARLOTTE, N.C., Aug. 20, 2012 /- Robert Steele has joined ARAMARK Healthcare Technologies as Vice President and General Manager of the organization's Goodlettsville, TN-based, ReMedPar business, it was announced today. In this role, Rob will lead the organization's customer service and technical operations, sales, marketing and administrative functions for the provider of quality...
Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief ProgramAugust 20, 2012 1:20 pm | by Bio-Medicine.Org | News | Comments
HAMPTON, Va., Aug. 20, 2012 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) is pleased to announce the receipt of a generous contribution that will have direct and immediate impact by allowing PAF to continue support to patients suffering with non-squamous non-small cell lung cancer (NSCLC) within its Co-Pay Relief Program (CPR). PAF's Co-Pay Relief Program provides direct financial...